Chest
Clinical InvestigationsCopdDual Energy X-ray Absorptiometry Outcomes in Male COPD Patients After Treatment With Different Glucocorticoid Regimens
Section snippets
Study Design
Previous uses of systemic GCs and ICS in a cohort of white male patients with COPD were carefully assessed from hospital patient records obtained at the pulmonary diseases outpatient clinic of the Reinier de Graaf Groep, in Delft and Voorburg, the Netherlands. Patients included in the study consulted one lung physician consecutively. Every new patient with COPD and all those with a previous diagnosis of COPD were invited to participate in the study. Informed consent was obtained from each
Patient Characteristics
As demonstrated in Table 1, the mean ages of patients in the four groups were similar, but body mass index (BMI) was lower in group 2. Group 4 consisted of 22 non-ICS and 15 ICS users (60 ± 14 years of age vs 69 ± 11 years of age; p < 0.05). In these two subgroups, spinal BMD outcomes were similar (1.17 ± 0.17 g/cm2 vs 1.12 ± 0.22 g/cm2; p < 0.44), but total hip and femoral neck BMD values were lower in the ICS users (0.98 ± 0.12 g/cm2 vs 0.88 ± 0.16 g/cm2, and 0.92 ± 0.12 g/cm2 vs 0.82 ±
Discussion
In this cross-sectional study, we tested the hypothesis that administration of multiple courses of GCs would elicit more harmful effects to bone than continuous GC treatment regimens. In the analysis, we calculated cumulative GCs usage throughout lifetime, and it was found that when adjusted for BMI and PFT, lowest spinal BMD was observed in patients receiving GC in multiple courses, lasting up to 2 weeks per course, > 1,000 mg of prednisolone cumulatively. Osteoporosis of the lumbar spine was
References (36)
- et al.
Inhaled corticosteroid use and bone mineral density in patients with asthma
Lancet
(2000) - et al.
Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men
Bone
(1998) - et al.
Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial
Lancet
(1999) - et al.
Decreased bone density in pre-menopausal asthma patients receiving long term inhaled steroids
Chest
(1994) - et al.
Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids
J Allergy Clin Immunol
(1995) - et al.
Bone loss in response to long-term glucocorticoid therapy
Bone Miner
(1990) - et al.
Reversibility of steroid-induced osteoporosis
Am J Med
(1988) Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease
N Engl J Med
(2000)- et al.
Use of oral corticosteroids and risk of fractures
J Bone Miner Res
(2000) - et al.
Steroid-induced fractures and bone loss in patients with asthma
N Engl J Med
(1983)
Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease
Am J Respir Crit Care Med
New developments in the pathogenesis and treatment of steroid-induced osteoporosis
J Bone Miner Res
Changes in calcium and bone metabolism during treatment with low dose prednisone in young, healthy, male volunteers
Clin Rheumatol
Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years
Thorax
Lung volumes and forced ventilatory flows: Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal; official statement of the European Respiratory Society
Eur Respir J Suppl
Osteoporosis in steroid-dependent asthma
Ann Allergy Asthma Immunol
Bone density in asthmatic patients taking high dose inhaled beclomethasone and intermittent systemic corticosteroids
Thorax
Effect of inhaled corticosteroid on bone density in asthmatic patients: a pilot study
Ann Allergy
Cited by (53)
Prevalence and Risk Factors for Osteoporosis in Individuals With COPD: A Systematic Review and Meta-analysis
2019, ChestCitation Excerpt :After excluding duplicates, the titles and abstracts of 1,926 articles were screened for eligibility. Of these, the full-text of 116 articles was screened for eligibility, resulting in the identification of 58 studies that were reported in 64 publications13-76 (Fig 1). All included studies were cross-sectional in design except two case-control studies36,38 and one longitudinal design.37
Prevention and management of glucocorticoid-induced side effects: A comprehensive review: A review of glucocorticoid pharmacology and bone health
2017, Journal of the American Academy of DermatologyCitation Excerpt :Conversely, there is currently no evidence that osteoporosis medication is needed to prevent fractures for patients on occasional dose-pack prescription glucocorticoids, replacement therapy for hypopituitarism or adrenal insufficiency, or short term high-dose intravenous or oral therapy with <1 g of cumulative annual exposure.14 For cumulative prednisolone doses of >1 g prescribed in short bursts even over the course of 1 year, significant bone loss has been seen.24 Cumulative corticosteroid dose strongly correlates with loss of bone mineral density.19,25
Chronic obstructive pulmonary disease and osteoporosis
2009, Seminarios de la Fundacion Espanola de ReumatologiaCorrelates of osteoporosis in chronic obstructive pulmonary disease: An underestimated systemic component
2009, Respiratory MedicineCitation Excerpt :Indeed, de Vries and colleagues found the influence of inhaled corticosteroids to disappear after correcting for airflow obstruction.27 In addition, the duration of treatment with oral corticosteroids, the number of courses and the cumulative dose were unknown, and different corticosteroid regimens had different effects on BMD.21 Further (longitudinal) research regarding these potential confounders of osteoporosis in COPD patients is needed.